Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

Summary

The purpose of this study is to evaluate the long term safety and tolerability of CDP6038 (olokizumab) treatment in adult subjects with active rheumatoid arthritis who completed study RA0056 (NCT01242488).

Timeline

Start

2011-03-07

Primary completion

2013-05-01

Completion

2013-08-05

Outcome

Outcome not reported

Stopped: “Decision to out-license the compound for further development”

Drugs

Indications